BioCentury
ARTICLE | Company News

Columbia University, Lin Bioscience deal

January 20, 2017 7:33 PM UTC

The university granted Lin Bioscience exclusive, worldwide rights to preclinical candidate LBS-008 and related IP. Lin expects to move the retinol binding protein 4 plasma (RBP4) inhibitor into Phase I testing this year to treat dry age-related macular degeneration (AMD) and Stargardt's disease. ...

BCIQ Company Profiles

Columbia University